| Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs. | |
MedLine Citation:
|
PMID: 17591655 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Animal models of diseases are widely used in the preclinical phase of drug development. They have a place in early human clinical psychopharmacology as well, in order to get early clues that contribute to establish the proof of concept (POC) already in healthy volunteers (HV). Different types of models are available (pharmacological or non-pharmacological provocation, models based on age-related characteristics). This review is focused on pharmacological models in HV, with the aim to identify the main issues raised by their use in pharmaceutical trials. The available models unevenly fulfil the requirements of face validity, sufficient response rate, test-retest consistence and responsiveness to reference drugs. Most of them have been developed in the purpose of pathophysiology studies, using rating instruments validated for clinical practice. Substantial progress could be made by adapting models to the specific requirements of pharmaceutical trials, including wider use of biomarkers. Characteristics that make models, as well as biomarkers, suitabLe for use in drug development are proposed. Despite obvious limitations, human models can significantly enhance the way phase I studies contribute to establish the POC, provided they are integrated into adapted phase I development plans. Their use as industrial tools for drug evaluation requires specific, dedicated development. |
Authors:
|
Christian Gilles; Remy Luthringer |
Related Documents
:
|
8493425 - Data monitoring and interim analyses in the pharmaceutical industry: ethical and logist... 11746315 - Combining components of quality of life to increase precision and evaluate trade-offs. 18044615 - Quantifying effect-specific mammographic density. 10471225 - On the scientific inference from clinical trials. 22419385 - The causal mediation formula-a guide to the assessment of pathways and mechanisms. 9052915 - Predictive ability of creatinine clearance estimate models in pediatric bone marrow tra... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of psychopharmacology (Oxford, England) Volume: 21 ISSN: 0269-8811 ISO Abbreviation: J. Psychopharmacol. (Oxford) Publication Date: 2007 May |
Date Detail:
|
Created Date: 2007-06-26 Completed Date: 2007-08-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8907828 Medline TA: J Psychopharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 272-82 Citation Subset: IM |
Affiliation:
|
Centre Hospitalier de l'Ardenne, Sainte Ode, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Apomorphine
/
pharmacology Cognition Disorders / chemically induced, psychology Dopamine Agonists / pharmacology Excitatory Amino Acid Antagonists / pharmacology GABA Modulators / pharmacology Humans Ketamine / pharmacology Lorazepam / pharmacology Memory Disorders / chemically induced, psychology Models, Psychological Muscarinic Antagonists / pharmacology Panic Disorder / chemically induced, drug therapy, physiopathology Psychotropic Drugs / pharmacology* Scopolamine / pharmacology Tryptophan / deficiency, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Dopamine Agonists; 0/Excitatory Amino Acid Antagonists; 0/GABA Modulators; 0/Muscarinic Antagonists; 0/Psychotropic Drugs; 51-34-3/Scopolamine; 58-00-4/Apomorphine; 6740-88-1/Ketamine; 73-22-3/Tryptophan; 846-49-1/Lorazepam |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-m...
Next Document: Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic d...